Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Paling

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Multiple Sclerosis and Related Disorders|January 30, 2026
Real-world evidence of clinical outcomes and adherence to ofatumumab in the UK and the impact of a patients support programme: A retrospective, non-interventional cohort studyDavid Paling, David Cottrell, Ruth Hamlin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 12, 2025
Baló's concentric sclerosis successfully treated with alemtuzumab: Long-term follow-upSandra Elias, Todd A Hardy, Aijaz Khan, et al.
Neurology|October 15, 2021
Mechanisms of Network Changes in Cognitive Impairment in Multiple SclerosisDanka Jandric, Ilona Lipp, David Paling, et al.
Brain : a Journal of Neurology|June 27, 2013
Sodium accumulation is associated with disability and a progressive course in multiple sclerosisDavid Paling, Bhavana S Solanky, Frank Riemer, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|September 19, 2013
Cerebral arterial bolus arrival time is prolonged in multiple sclerosis and associated with disabilityDavid Paling, Esben Thade Petersen, Daniel J Tozer, et al.
Multiple Sclerosis and Related Disorders|December 11, 2025
Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosisStephen L Hauser, Mark S Freedman, Jin Nakahara, et al.
Multiple Sclerosis and Related Disorders|May 7, 2024
Prevalence, treatment and correlates of depression in multiple sclerosisCarolyn A Young, Dawn Langdon, David Rog, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|October 13, 2023
Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosisJohn Kramer, Ralf Linker, David Paling, et al.
BMJ Neurology Open|March 8, 2021
Effect of remote ischaemic preconditioning on walking in people with multiple sclerosis: double-blind randomised controlled trialChayaporn Chotiyarnwong, Krishnan Nair, Lorenza Angelini, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 7, 2020
Simultaneous ALS and SCA2 associated with an intermediate-length <i>ATXN2</i> CAG-repeat expansionHelia Ghahremani Nezhad, John P Franklin, James J P Alix, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Multiple Sclerosis and Related Disorders|January 30, 2026
Real-world evidence of clinical outcomes and adherence to ofatumumab in the UK and the impact of a patients support programme: A retrospective, non-interventional cohort studyDavid Paling, David Cottrell, Ruth Hamlin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 12, 2025
Baló's concentric sclerosis successfully treated with alemtuzumab: Long-term follow-upSandra Elias, Todd A Hardy, Aijaz Khan, et al.
Neurology|October 15, 2021
Mechanisms of Network Changes in Cognitive Impairment in Multiple SclerosisDanka Jandric, Ilona Lipp, David Paling, et al.
Brain : a Journal of Neurology|June 27, 2013
Sodium accumulation is associated with disability and a progressive course in multiple sclerosisDavid Paling, Bhavana S Solanky, Frank Riemer, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|September 19, 2013
Cerebral arterial bolus arrival time is prolonged in multiple sclerosis and associated with disabilityDavid Paling, Esben Thade Petersen, Daniel J Tozer, et al.
Multiple Sclerosis and Related Disorders|December 11, 2025
Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosisStephen L Hauser, Mark S Freedman, Jin Nakahara, et al.
Multiple Sclerosis and Related Disorders|May 7, 2024
Prevalence, treatment and correlates of depression in multiple sclerosisCarolyn A Young, Dawn Langdon, David Rog, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|October 13, 2023
Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosisJohn Kramer, Ralf Linker, David Paling, et al.
BMJ Neurology Open|March 8, 2021
Effect of remote ischaemic preconditioning on walking in people with multiple sclerosis: double-blind randomised controlled trialChayaporn Chotiyarnwong, Krishnan Nair, Lorenza Angelini, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 7, 2020
Simultaneous ALS and SCA2 associated with an intermediate-length <i>ATXN2</i> CAG-repeat expansionHelia Ghahremani Nezhad, John P Franklin, James J P Alix, et al.
Pageof 4